glp-1 agonist indications FDA-Approved Dosages and for and Dual GIP/GLP-1 GLP-1 medicines for weight loss

Tschoepe D

10.1016/j.jep.2023.117556 36 WeiM.ZhengZ.ShiL.JinY.JiL

The following table describes GLP-1 receptor agonists, their dosing frequency and key pharmacokinetic parameters: Cautions and Contraindications Adverse Effects Acute pancreatitis (rare) Injection site reactions Gastrointestinal disturbances (nausea, vomiting, diarrhoea dehydration and possible renal impairment) Increase in pancreatic enzymes: lipase and amylase (dulaglutide, tirzepatide and semaglutide) Cholecystitis and cholelithiasis Delayed gastric emptying (semaglutide, exenatide, dulaglutide, tirzepatide (diminishes over time)) Increased heart rate Diabetic retinopathy complications (semaglutide, particularly in insulin-treated patients with known diabetic retinopathy) Interactions GLP-1 receptor agonists do not interact via cytochrome P450 , but delayed gastric emptying may alter drug absorption

Nano Lett 20 , 45434549 (2020)

During your visit, we talk through what youre experiencing day to day and create a plan that feels realistic and supportive, not overwhelming

Common benefits include: These injections are an excellent option for individuals looking to accelerate progress in their weight management plan or overcome plateaus